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ABSTRACT
Mediator is a multiprotein co-activator of RNA poly-
merase (Pol) II transcription. Mediator contains a
conserved core that comprises the ‘head’ and
‘middle’ modules. We present here a structure–
function analysis of the essential Med11/22 hetero-
dimer, a part of the head module. Med11/22 forms a
conserved four-helix bundle domain with C-terminal
extensions, which bind the central head subunit
Med17. A highly conserved patch on the bundle
surface is required for stable transcription pre-
initiation complex formation on a Pol II promoter
in vitro and in vivo and may recruit the general tran-
scription factor TFIIH. The bundle domain fold is
also present in the Mediator middle module sub-
complex Med7/21 and is predicted in the Mediator
heterodimers Med2/3, Med4/9, Med10/14 and
Med28/30. The bundle domain thus represents a
common building block that has been multiplied
and functionally diversified during Mediator evolu-
tion in eukaryotes.
INTRODUCTION
Transcription of eukaryotic protein-coding genes and
several non-coding RNAs relies on Pol II, a set of
general transcription factors (GTFs), namely TFIIB, D,
E, F and H and co-activators such as the Mediator
complex (1,2). While the GTFs are required for promoter
recognition and opening, transcription start site selection
and initial RNA synthesis, Mediator bridges between the
general Pol II machinery and transcriptional activators
at upstream DNA sites (3–6). Upon activator binding,
Mediator undergoes conformational changes, which trig-
ger its interaction with Pol II and promote pre-initiation
complex (PIC) formation (7).
Mediator was puriﬁed from yeast (8,9), metazoans
(10,11) and plants (12). Comparative genomics identiﬁed
an ancient 17-subunit Mediator core that is conserved
in eukaryotes (13,14). Mediator from the yeast
Saccharomyces cerevisiae (Sc) is a 1.4 MDa multiprotein
complex comprising 25 subunits, of which 11 are essential
and 22 are at least partially conserved. Based on electron
microscopy and biochemical analysis, mediator subunits
were suggested to reside in four ﬂexibly linked modules,
the head, middle, tail and kinase module (15–17). The Sc
head module comprises ﬁve essential subunits, Med6,
Med8, Med11, Med17 (Srb4) and Med22 (Srb6) and two
non-essential subunits, Med18 (Srb5) and Med20 (Srb2).
The head module is important for PIC assembly. It
contacts the Pol II-TFIIF complex (18), the TATA
binding protein (TBP) (16,19), TFIIB (16) and TFIIH
(20). A temperature-sensitive mutation in the central
head subunit Med17 (srb4-138) affects head module integ-
rity, abolishes stimulation of basal transcription in vitro
(18), prevents association of Pol II and GTFs with pro-
moters in vivo (21,22) and causes a global shutdown of
messenger RNA (mRNA) synthesis (23,24). Sc Med11
and Med22 bind and stabilize Med17 (16,18). A
temperature-sensitive mutation in Med22 (srb6-107)
causes a global decrease in mRNA synthesis, similar to
srb4-138 (24). Point mutations in Med22 can act as extra-
genic suppressors of the srb4-138 phenotype (25), of the
cold-sensitive phenotype of the Pol II C-terminal domain
(CTD) truncation (26) and of the lethal CTD Ser2 phos-
phorylation site substitution mutation (27). Med11 inter-
acts with the Rad3 subunit of TFIIH in a yeast two-hybrid
assay and a point mutation in Med11 reduced promoter
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sequently CTD Ser5 phosphorylation in vivo (20).
In this study, we show that Med11 and Med22 form a
heterodimeric Med11/22 subcomplex. We describe a
Med11 homologue in the yeast Schizosaccharomyces
pombe (Sp) that had not been identiﬁed (28), strongly
arguing that the Med11/22 subcomplex is conserved
amongst eukaryotes. We further show that Med11/22
forms a four-helix bundle domain with similarity to the
Med7/21 subcomplex in the middle module. We also dem-
onstrate that the bundle is anchored to a C-terminal
region of the central head subunit Med17 that appears
to form an independently folded domain. We further
identiﬁed a highly conserved surface patch on the bundle
domain. This patch is required for Pol II transcription
in vitro and in vivo and for stable PIC formation.
Finally, we predict four additional heterodimeric four-
helix bundles in Mediator, suggesting that this fold repre-
sents a common building block and providing insights into
the evolution of Mediator.
MATERIALS AND METHODS
Preparation of recombinant Med11/22 variants
For recombinant expression of the heterodimeric Sc
Med11/22 complex, the coding sequences were cloned as
a bicistron (19) into a pET28b vector (Novagen) using
NdeI/XhoI restriction sites resulting in a thrombin-
cleavable N-terminal hexahistidine (6His) tag on Med22.
Two point mutations were introduced to remove alterna-
tive bacterial start codons, nucleotide G132C in MED11
(no change in amino acid sequence) and nucleotide G81A
in MED22 (amino acid change Met27Ile). Transformed
Escherichia coli (E. coli) BL21 (DE3) RIL cells
(Stratagene) were grown in LB medium at 37 Ct oa n
optical density at 600nm (OD600) of 0.6. Expression was
induced with 0.5mM IPTG for 16h at 18 C.
Selenomethionine labeling was carried out as described
(45,46). Cells were lysed by sonication in buffer A
(20mM Tris pH 8.0, 150mM NaCl, 2mM dithiothreitol)
containing protease inhibitor cocktail (1mM Leupetin,
2mM Pepstatin A, 100mM Phenylmethylsulfonyl
ﬂuoride, 280mM Benzamidine). After centrifugation, the
supernatant was loaded onto a 2ml Ni-NTA column
(Qiagen) equilibrated with buffer A. The column was
washed with 10 column volumes (CVs) of buffer A con-
taining 10mM imidazole and with 10 CVs of buffer A
containing 20mM imidazole. The complex was eluted
with buffer A containing 300mM imidazole followed by
overnight cleavage with thrombin while dialyzing against
buffer B (20mM Tris pH 8.0, 50mM NaCl, 2mM
dithiothreitol). The proteins were further puriﬁed by
anion exchange chromatography using a HiTrap Q HP
column (GE Healthcare). The column was equilibrated
with buffer B and the complex was eluted with a linear
gradient of 25 CVs from 50 to 500mM NaCl in buffer B.
Subsequently, the sample was applied to a HiLoad
Superdex-75pg 26/60 size exclusion column (GE
Healthcare) equilibrated with buffer A.
X-ray structure determination
For crystallization, the puriﬁed selenomethionine-
labeled complex Med111-89/Med225-89 was concentrated
to 10mg/ml. Crystals were grown at 20 C in hanging
drops over reservoirs containing 100mM MES pH 6,
5.5% PEG 6000 and 100mM MgCl2. Microseeding was
performed to optimize crystals. Initial crystals were
transferred into 100ml reservoir solution and vortexed vig-
orously. 0.2ml of the resulting microseeding solution was
added to each 2ml drop to nucleate crystal growth.
Optimized crystals were harvested by gradually adding
glycerol to a ﬁnal concentration of 34% (v/v) and were
subsequently ﬂash-frozen in liquid nitrogen. Diffraction
data was collected at 100K on a PILATUS 6M detector
at the Swiss Light Source SLS, Villigen, Switzerland.
Diffraction data were processed using XDS and
XSCALE (47). The program SOLVE (48) identiﬁed 36
selenium sites in the asymmetric unit that were used for
phasing.Solventﬂattening,non-crystallographicsymmetry
averaging and initial model building were done with
RESOLVE (48) and ARP/warp (49). The resulting elec-
tron density map allowed for manual building of most of
Med11 and Med22 using COOT (50). The model was re-
ﬁned using conjugate gradient minimization in PHENIX
(51). The asymmetric unit contained twelve Med11/22
heterodimers that deviated only slightly at the C–termini
of the proteins. All structure ﬁgures depict chain A/B and
were prepared using PyMOL (52).
Yeast strains and growth assays
Plasmids pRS316-MED11 and pRS316-MED22 were
generated by cloning the respective open reading frame
(ORF) plus 500bp upstream and 300bp downstream se-
quences into pRS316 (ATCC; URA3 marker) using SacII/
ApaI restriction sites. Plasmids pRS315-MED11, pRS315-
med1143–115, pRS315-med111–110, pRS315-med111–105,
pRS315-med111–89, pRS315-med11-E17K/L24K, pRS315-
med11-L73E/K80E, pRS315-med11-K80E/L84E, pRS315-
med111–105-3HA, pRS315-med11-E17K/L24K-3HA,
pRS315-MED22, pRS315-med2254–121, pRS315-med221–
117, pRS315-med221–108 and pRS315-med221–89 were gene-
rated by cloning the respective ORF or mutant ORF plus
500bp upstream and 300bp downstream sequence into
pRS315 (ATCC; LEU2 marker) using SacII/ApaI restric-
tion sites. The heterozygous MED11/med11 and
MED22/med22 Sc yeast strains were obtained from
Euroscarf (Frankfurt, Germany) and transformed with
pRS316-MED11 and pRS316-MED22 respectively.
Diploids were sporulated and tetrads dissected on YPD
plates. To assess functionality of mutants, pRS315
constructs were transformed into the respective shufﬂe
strain. Equal amounts of freshly grown yeast cells in SC
(-ura/-leu) were resuspended in water and 10-fold dilutions
were spotted on 5-FOA and SC (-ura/-leu) plates. Viable
mutant strains were streaked twice on 5-FOA plates and
then on SC (-leu). Equal amounts of freshly grown yeast
cells in SC (-leu) were resuspended in water, 10-fold
dilutions were spotted on YPD plates and plates were sub-
sequently incubated at 30 C and 37 C to assess ﬁtness and
temperature sensitivity. MED11 shufﬂe strains expressing
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Kin28, Med7 and Rpb3 were generated by integrating a
TAP-HIS3MX cassette in the respective genomic locus.
The Sc wild-type strain BY4741 as well as med20 and
med2 strains used for gene expression proﬁling were
obtained from Open Biosystems. Correct gene disruptions
and TAP-insertions were veriﬁed by PCR for all strains.
Sp wild-type strain 972h- was used in this study.
C-terminal TAP-tag on Med7 and C-terminal 3HA-tag
on Med11 were introduced by integrating a TAP-
KanMX4 cassette and a 3HA-ClonNat cassette in the
respective genomic locus.
TAP
TAP were performed as described from 3l of Sc culture
(5 10
7 cells/ml) grown at 30 C in YPD medium with 2%
glucose or from 2l of Sp culture (OD600 of 6) grown at
32 C in YPD medium with 3% glucose (29,53). For
small-scale co-immunoprecipitation in Sc 40ml cultures
(1   10
7 cells/ml) were grown. After centrifugation, the
cells were resuspended in 1ml TAP lysis buffer (50mM
Tris pH 7.5, 100mM NaCl, 1.5mM MgCl2, 0.15% NP-40,
0.5mM DTT and protease inhibitor cocktail) and 1ml
silica-zirconia beads (Roth) was added. Lysis was done
in a mixer mill (Retsch) at 4 C for 30min at maximum
speed. The cleared lysate was incubated with 25ml IgG
Sepharose 6 Fast Flow beads (GE Healthcare) at 4 C
for 1h on a turning wheel. After washing 5  with 1ml
TAP lysis buffer, the proteins were eluted by boiling beads
in SDS–PAGE sample buffer.
Recombinant protein interaction assays
Plasmids encoding Sc 6His-Med22/Med11 variants were
generated as described above. Sc Med17C (residues
377–687) was cloned into a pET21b vector (Novagen)
using SalI/NotI restriction sites. A non-cleavable
C-terminal 6His tag followed by a stop codon was intro-
duced by PCR where applicable. The Sp His6-Med22/
Med11 constructs were cloned as a bicistron into
pET28b vector (Novagen) using NdeI/SacI restriction
sites. The Sp Med17 was inserted into pCDF-Duet
vector (Novagen) using NcoI/NotI restriction sites. For
co-expression and co-puriﬁcation the respective plasmids
were co-transformed in E. coli BL21 (DE3) RIL cells
(Stratagene) and grown in 5ml LB medium at 37 Ct o
an OD600 of 0.6. Expression was induced with 0.5mM
IPTG for 16h at 18 C. Cells were harvested and resus-
pended in 1ml lysis buffer (20mM Tris pH 8.0, 150mM
NaCl, 2.5mM MgCl2, 0.1mM CaCl2, 10% glycerol, 1%
Tween-20, 2mg/ml lysozyme, 1U/ml DNAse I, 2mM
DTT and protease inhibitor cocktail). Cell suspension
was ﬂash-frozen in liquid nitrogen then thawed and
incubated for 1h at 20 C while shaking. After centrifuga-
tion, the supernatant was incubated with 10ml MagneHis
beads (Promega) for 10min at 4 C on a turning wheel.
Beads were washed once with wash buffer (20mM Tris
pH 8.0, 5mM DTT) containing 500mM NaCl and twice
with wash buffer containing 150mM NaCl. Proteins
were eluted with wash buffer containing 150mM NaCl
and 500mM imidazole. Proteins were analyzed by
SDS–PAGE and stained with coomassie blue.
In vitro assays with yeast nuclear extracts
Yeast nuclear extract preparation, in vitro transcription
and immobilized template assay were done as described
(41,54) with some changes. For yeast nuclear extract prep-
aration 3l of Sc were grown to 5   10
7 cells/ml in YPD
with 2% glucose. Cells were harvested by centrifugation
and the pellet was resuspended in 30ml resuspension
buffer (50mM Tris pH 7.5, 20mM EDTA, 30mM
DTT) and incubated at 30 C for 15min. Afterwards,
cells were centrifuged and resuspended in 20ml YPD/S,
3ml 2M sorbitol, 3ml resuspension buffer containing
18mg zymolyase (Seikagaku) and protease inhibitor cock-
tail. Cells were incubated at 30 C for 15–60min until
 85% of cells were spheroplasted. A quantity of 100ml
of YPD/S was added and cells were centrifuged. Pellet was
resuspended in 250ml YPD/S and incubated at 30 C for
30min. Afterwards, cells were washed twice with 200ml
ice-cold YPD/S and once with 200ml 1M ice-cold
sorbitol. Cells were resuspended in 100ml ice-cold buffer
A (10mM Tris pH 7.5, 18% polysucrose 400, 20mM po-
tassium acetate, 5mM magnesium acetate, 1mM EDTA,
0.5mM spermidine, 0.15mM spermine, 3mM DTT and
protease inhibitor cocktail) and lysed on ice in a Dounce
glass homogenizer (Kontes) with a small pestle. Crude
nuclei were isolated by centrifuging twice at 3800g for
8min and twice for 5min, transferring the supernatant
each time to a new bottle. Afterwards, nuclei were
centrifuged at 20000g, washed once with 15ml buffer B
(100mM Tris pH 8.0, 50mM potassium acetate, 10mM
magnesium sulfate, 20% glycerol, 2mM EDTA, 3mM
DTT and protease inhibitor cocktail) and ﬂash-frozen in
15ml fresh buffer B. The next day the nuclei were lysed by
adding (NH4)2SO4 (pH 7.5) to a ﬁnal concentration of
0.5M and incubated at 4 C for 30min on a turning
wheel. Afterwards, nuclear lysate was centrifuged at
140000g for 90min at 4 C. Nuclear proteins in the super-
natant were precipitated by addition of solid 0.35g
(NH4)2SO4/ml and incubation at 4 C for 30min on a
turning wheel. After centrifugation, the nuclear proteins
were resuspended in a small volume of buffer C (20mM
HEPES pH 7.6, 10mM magnesium sulfate, 1mM EGTA,
20% glycerol, 3mM DTT and protease inhibitor cocktail)
and dialyzed against buffer C containing 75mM
(NH4)2SO4. Nuclear extracts were ﬂash frozen in liquid
nitrogen and stored at  80 C.
Pol II in vitro transcription was driven from a wild-type
HIS4 yeast promoter sequence ( 428 to+24 respective to
the start codon) inserted into pBluescript II KS+plasmid
using HindIII/BamHI restriction sites. The 25ml reaction
mixture contained 200mg yeast nuclear extract, 200ng of
template plasmid, transcription buffer (10mM HEPES
pH 7.6, 50mM potassium acetate, 0.5mM EDTA,
2.5mM magnesium acetate, 2.5mM DTT), 192mg of phos-
phocreatine, 0.2mg of creatine phosphokinase, 10U of
RiboLock RNase inhibitor (Fermentas) and 100mM
nucleoside triphosphates (NTPs). For activated transcrip-
tion, 200ng of recombinant full-length Gcn4 was added.
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isolated using the RNeasy MinElute kit (Qiagen). RNA
was eluted from the column with 14ml RNase-free water
and in vitro transcripts were analyzed by primer extension.
The 20ml primer annealing reaction contained 12ml eluate
from RNeasy MinElute column, 0.125pmol ﬂuorescently
labeled oligo (50-Cy5-TTCACCAGTGAGACGGGCAA
CAGCCAAGCTC), 5mM Tris pH 8.3, 75mM KCl and
1mM EDTA pH 8.0. After boiling the samples for 3min
at 95 C, primer was annealed for 45min at 48 C.
Afterwards, 40ml reverse transcription mix [50 mM Tris
pH 8.3, 75mM KCl, 4.5mM MgCl2, 25mM DTT,
0.3mM dNTPs, 12.5U MuLV reverse transcriptase
(Roche) and 1mg actinomycin D] was added and the
reaction was incubated for 30min at 37 C. The resulting
cDNA was ethanol precipitated and resuspended in 4ml
0.04mg/ml RNase A. After incubating 3min at 18 C4ml
loading dye were added (80% formamide, 25mM EDTA,
1.5% bromophenolblue) and the samples were boiled for
1min. Transcripts were separated on a 8% polyacryl-
amide/7M urea TBE gel, scanned with a Typhoon 9400
and quantiﬁed with the ImageQuant software (GE
Healthcare).
Pol II immobilized template assays were done on a
linear yeast HIS4 promoter. Templates were ampliﬁed
by PCR from the template plasmid described above
(forward primer: 50-biotin-TAATGCAGCTGGCACGA
CAGG; reverse primer: 50-GCCGCTCTAGCTGCATT
AATG) and puriﬁed with PCR puriﬁcation kit (Qiagen)
and phenol–chloroform extraction. A quantity of 200mg
of magnetic streptavidin beads (Dynabeads M-280,
Invitrogen) were used per reaction carrying  2.5pmol of
template. Coupled beads were blocked for 15min at 20 C
with transcription buffer containing 60mg/ml casein and
5mg/ml polyvinylpyrrolidone and subsequently for 15min
at 20 C with transcription buffer containing 0.5mM
biotin. After washing, beads were resuspended in 20ml
transcription buffer, 5pmol recombinant full-length
Gcn4 were added and incubated for 10min at 20 C
while shaking. Afterwards, beads were washed twice
and again resuspended in 20ml transcription buffer.
Immobilized template reaction of 100ml contained 20ml
beads, 1mg yeast nuclear extract, 5mg competitor DNA
(HaeIII digested genomic E. coli DNA), transcription
buffer, 768mg of phosphocreatine, 0.8mg of creatine
phosphokinase, 0.05% NP-40. Assembly was done for
1h at 4 C while shaking followed by washing twice with
transcription buffer containing 2mg/ml competitor DNA,
twice with transcription buffer containing 500mM potas-
sium acetate and twice with transcription buffer. Proteins
were eluted by boiling beads in SDS-loading dye and
subsequently analyzed by SDS–PAGE and western blot.
Antibodies against Med2 (Santa Cruz), Rpb3 (Neoclone),
Rpb11 (Neoclone), Srb4 (gift of the Hahn laboratory),
TAF4 (Abcam), TFIIB (Abcam) were used in this study.
Gene expression proﬁling
All experiments were performed in YPD medium with 2%
glucose. For microarray analysis, at least two independent
colonies were used for inoculation and overnight cultures
were diluted in fresh medium to 1 10
6 cells/ml (25ml
cultures, 160rpm shaking incubator, 30 C). Cells were
harvested in early log-phase (1 10
7 cells/ml) by centrifu-
gation. Total RNA was prepared after cell lysis using a
mixer mill (Retsch) and subsequent puriﬁcation using the
RNAeasy kit (Qiagen). Total RNA was prepared with the
RiboPureYeast Kit (Ambion) following the manufactur-
er’s instructions. All following steps were conducted ac-
cording to the Affymetrix GeneChip 30IVT Kit protocol.
Brieﬂy, one-cycle cDNA synthesis was performed with
250–300ng of total RNA. In vitro reverse transcription
labeling was carried out for 16h. The fragmented
samples were hybridized for 16h on Yeast Genome 2.0
expression arrays (Affymetrix), washed and stained using
a Fluidics 450 station and scanned on an Affymetrix
GeneArray scanner 3000 7G. Data analysis was per-
formed using R/Bioconductor (55). Sp probes were
ﬁltered out prior to normalization with the GCRMA al-
gorithm (56). Linear model ﬁtting and multiple testing
correction using an empirical Bayes approach was per-
formed using the LIMMA package (57). Differentially ex-
pressed genes were deﬁned as having an adjusted P<0.05
and an estimated fold change >2.0 (calculated as the fold
change of the average expression in the triplicate measure-
ments). Hierarchical clustering was calculated using TIGR
MeV application (58). Gene ontology (GO) analysis (38)
of differentially expressed genes was performed to identify
overrepresented biological processes using the GO term
ﬁnder web tool (http://go.princeton.edu/cgi-bin/
GOTermFinder).
Chromatin immunoprecipitation
All chromatin immunoprecipitation experiments were
performed in biological duplicates in YPD medium with
2% glucose as previously described in detail (59,60). Since
the Med11/22 mutant strains displayed severe growth
defects and larger cell sizes compared to wild-type, cells
were counted instead of measuring optical density. To
minimize the risk of acquiring a rescue mutation and
ensure biological signiﬁcance of our observations, the
used biological duplicates were already separated before
shufﬂing out the respective rescue plasmid and several
rounds of selection. Phenotype and growth was monitored
closely at each step. Overnight cultures were diluted in
fresh medium to 1 10
6cells/ml (40ml cultures, 160rpm
shaking incubator, 30 C) and grown to early log-phase
(1 10
7cells/ml) before formaldehyde cross-linking.
Input and immunoprecipitated samples were assayed by
quantitative real-time PCR to assess occupancy of proteins
at three different promoters. Primer pairs directed against
the promoter of the highly transcribed ILV5 gene (ACCC
AGTATTTTCCCTTTCC; TTGTCTATATGTTTTTGT
CTTGC), the housekeeping gene ADH1 (TTTCCTTCC
TTCATTCACGCACA; TCAAGTAACTGGAAGGAA
GGCCGTA), the glucose-repressed GAL1 gene (GGGT
AATTAATCAGCGAAGC; GGTTATGCAGCTTTTC
CATT) as well as against a heterochromatic control
region of chromosome V (TGCGTACAAAAAGTGTC
AAGAGATT; ATGCGCAAGAAGGTGCCTAT) were
used. All primer pairs had PCR efﬁciencies in the range
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DNA template, 2mlo f1 0mM primer pairs and 12.5ml iTaq
SYBR Green Supermix (Bio-Rad). Quantitative PCR was
performed on a Bio-Rad CFX96 Real-Time System
(Bio-Rad Laboratories, Inc.) using a 3min denaturing
step at 95 C, followed by 49 cycles of 30s at 95 C, 30s
at 61 C and 15s at 72 C. Threshold cycle (Ct) values were
determined using the Ct determination mode ‘Regression’
of Bio-Rad CFX Manager software package (Version 1.1).
Fold enrichment over heterochromatic control region was
determined and calculated as described (59).
RESULTS
Revised Med11 N-terminus
Based on published interaction data, we assumed that Sc
Med11 and Med22 form a stable heterodimer. Indeed, the
two subunits could be co-expressed in recombinant form
(19,29) in E. coli and subsequently co-puriﬁed. When we
analyzed recombinant Med11/22 and endogenous puriﬁed
Mediator by SDS–PAGE, we noticed a discrepancy in the
electrophoretic mobility of Med11 (data not shown).
Endogenous Med11 appeared smaller than the variant ex-
pressed recombinantly. A comparison of the annotated
MED11 ORF with experimentally determined transcrip-
tion start sites derived from cDNA sequencing of full-
length 50-capped mRNAs (30) revealed that the start
codon of MED11 was incorrectly assigned in the data-
bases. The real initiator methionine corresponds to residue
17 of the original annotation; thus, the real protein is
smaller than previously thought. We corrected the amino
acid numbering and used the new numbering throughout.
Med11/22 structure solution
We prepared the correct full-length recombinant Med11/
22 heterodimer in pure recombinant form. In contrast to
the initial preparation, this complex crystallized. The
crystals could, however, not be reﬁned, likely due to ﬂexi-
bility in the poorly conserved C-termini of both subunits.
We, therefore, tested various truncated protein variants
for their solubility and crystallization behavior and
found that a variant comprising the highly conserved core
of Med11/22 (Med115–89/Med221–89, Figure 1) resulted in
crystals diffracting up to a resolution of 2.1A ˚ . The X-ray
structure was solved by selenomethionine labeling and
multi-wavelength anomalous diffraction and was reﬁned
to a free Rfactor of 20.8% (Table 1). The crystals contained
an unusual sphere-like arrangement of 12 heterodimers in
the asymmetric unit (Figure 1B). Disordered in the crystals
was only a non-conserved Med22 linker (residues 33–40)
between helix a1 and the non-conserved helix a*. Deletion
of this linker in yeast had no phenotype (Supplementary
Figure S1).
A helix bundle building block in Mediator
Med11/22 forms an antiparallel four-helix bundle
(Figure 1C). This bundle fold is required in vivo since
deletion of helix a1 in Med11 (med1143–115) was lethal in
yeast and deletion of a1 and a* of Med22 (med2254–121)
caused a growth defect (Figure 2). Unexpectedly, the
bundle fold resembles the previously reported structure
of the heterodimeric Med7C/21 subcomplex of the
middle module (31). The Med11/22 and Med7C/21 struc-
tures show a root mean square deviation of 3.1A ˚ over
121Ca atoms (Figure 1E). By combining results from
HHPred (32) and secondary structure predictions, we
detected a total of six possible heterodimeric four-helix
bundles in Mediator. Nine out of 17 Mediator core
subunits and two metazoan-speciﬁc subunits could partici-
pate in bundle formation (Figure 3 and Supplementary
Table S1). Heterodimer formation has been experimental-
ly veriﬁed for Med11/22 in the head (this study), Med4/9
(33) and Med7/21 (31) in the middle and Med2/3 in the
tail (34). Additional bundles are apparently present in the
Med10/14 heterodimer in the middle module (33) and in a
metazoan-speciﬁc Med28/30 subcomplex. These results es-
tablish the four-helix bundle fold as a common building
block of Mediator that is apparently found in all modules
except for the dissociable kinase module.
Essential C-terminal helices extend from the Med11/22
helix bundle
In the structure of Med7C/21 (31), the four-helix bundle is
connected to C-terminal helical extensions from both sub-
units that form a coiled-coil (Figure 1F). The C-terminal
extensions of Med11 and Med22 are not present in the
Med11/22 structure, but are predicted to each contain
an additional helix (Figure 1A and Supplementary
Figure S2). However, in contrast to Med7C/21, the
C-terminal helices are not predicted to form a coiled-coil
and are connected to the bundle through longer, probably
ﬂexible linkers. To investigate the importance of the pre-
dicted Med11/22C-terminal helices in vivo, we generated
several Med11/22 truncation variants (Figure 1A) and
tested them in yeast complementation assays (Figure 2).
Removal of either helix (med111–89 or med221–89)o r
even partial truncation of the Med22 C-terminal helix
(med221–108) was lethal under standard conditions. Thus,
the apparently ﬂexible and helical C-terminal extensions
from the Med11/22 bundle are required for normal cell
growth.
Med11/22 extensions bind a Med17 C-terminal domain
We next asked whether the C-terminal extensions anchor
the Med11/22 bundle within the head module by an inter-
action with Med17, the architectural head subunit. We
could indeed detect in vitro binding of Med11/22 to a
soluble C-terminal domain of Med17 (Med17C, residues
377–687) (Figure 4A, lanes 1 and 3). To map the Med17
binding determinant in Med11/22, we co-expressed and
co-puriﬁed truncated Med11/22 variants with Med17C
in E. coli. Recombinant Med11/22 heterodimers contain-
ing Med1143–115 could not be co-puriﬁed, whereas
Med111–89, Med111–105, Med2254–121 and Med221–89 all
formed stable complexes (Figure 4A). Truncation of
either predicted C-terminal helix (Figure 4A, lanes 6, 7,
10–12) prevented co-puriﬁcation of Med17C with Med11/
22, while truncation of the Med22 N-terminus (Figure 4A,
lane 4) or C-terminal truncations that did not affect the
Nucleic Acids Research, 2011,Vol.39, No. 14 6295Figure 1. Structure of Med11/22 Mediator subcomplex. (A) Multiple sequence alignment of the conserved core of Med11 and Med22 from
Saccharomyces cerevisiae (Sc), Schizosaccharomyces pombe (Sp), Caenorhabditis elegans (Ce), Drosophila melanogaster (Dm) and Homo sapiens
(Hs). The corrected numbering of Sc Med11 is used. Invariant and conserved residues are highlighted in green and yellow, respectively. Additionally,
residues that are invariant or conserved among the yeast family Saccharomycotinae (Sc, Candida glabrata, Candida albicans, Ashbya gossypii,
Kluyveromyce lactis and Debaryomyces hansenii) are highlighted with green and yellow frames on the Sc sequence, respectively. Surface accessibility
is indicated below the sequences (blue, high; cyan, intermediate; white, buried). Secondary structure elements of the conserved structural core are
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(continued)C-terminal helices (Figure 4A, lanes 5 and 9) had no
effect. We conclude that the C-terminal helices of
Med11/22 anchor the four-helix bundle to Med17C and
that the C-terminus of Med22 is absolutely required for
this interaction in vitro and in vivo. This is in accordance
with yeast two-hybrid results showing that the Sc Med11–
Med17 interaction is lost upon C-terminal truncation of
Med11 (20). The consistency of these in vitro binding data
with the above in vivo phenotyping further suggests that
Med11/22 anchoring to Med17C is essential for cellular
growth.
A conserved Med17C/11/22 Mediator subcomplex
The helix bundle of Med11/22 appears to be conserved
among eukaryotes, because amino acid residues that consti-
tute the Med11–Med22 interface are conserved (Figure 1D).
However, a Med11 homolog has thus far not been found
in Sp (28). We could however predict a remote Med11
homology in the Sp protein SPAC644.10 (35). Indeed,
Sp SPAC644.10 could be co-immunoprecipitated with
Med7, suggesting it is a Mediator subunit (Figure 4B).
Ampliﬁcation and sequencing of the SPAC644.10 cDNA
clone revealed the absence of an annotated intron and
enabled co-expression and co-puriﬁcation of recombinant
Sp SPAC644.10 with Sp Med22 (Figure 4). This estab-
lishes SPAC644.10 as the Sp Med11 homolog and conﬁrms
the conservation of the Med11/22 bundle. To investigate
whether the conservation extends to the anchoring of
Med11/22 on Med17C, we tested whether a trimeric Sp
Med17/11/22 subcomplex could be obtained after subunit
co-expression in E. coli and this was indeed achieved
(Figure 4C, lane 1). We mapped a soluble C-terminal
domain of Sp Med17 (Med17C, residues 257–545) that
was sufﬁcient for Med11/22 binding (Figure 4C, lane 4).
Truncation of the C-terminus of Sp Med22 did not affect
Med11/22 heterodimer formation, but abolished Med17
binding (Figure 4C, lane 3 and 6). Truncation of the
C-terminus of Sp Med11 (Med111–91) had almost no
effect (Figure 4C, lane 2 and 5). Thus, the interaction of
the C-terminal extension from the Med11/22 bundle with
Med17C is conserved between the distantly related yeast
Figure 1. Continued
shown above the sequences (spirals, a-helices; lines, ordered but without secondary structure; dashed lines, disordered in crystal construct). In
addition schematic views of the full proteins are shown. Consensus secondary structure predictions (61–63) for the C-termini of Sc Med11 and
Med22 are indicated with dashed lines and gray ﬁlling. All truncations relevant for this study are indicated with arrows and the residue number.
Previously reported as well as mutations generated in this study are marked with ﬁlled triangles. Sequence alignments were done with MUSCLE (64)
and ﬁgures were prepared with ESPript (65). (B) Ribbon-model representation of the 12 heterodimers within the asymmetric unit. Med11 and Med22
are depicted in brown and cyan, respectively. (C) Ribbon-model representation of the Med11/22 crystal structure. Secondary structure elements are
labeled according to (A). The linker between helices a1 and a* of Med22 (residues 33–40) was disordered. C-termini of Med11 and Med22 had to be
removed from crystallization construct and are therefore lacking in the structure. (D) Dimer interface conservation. On the left, Med11 is shown in
surface representation together with a ribbon model of Med22. The view is related to (C) by a 90  rotation around a vertical axis. On the right,
Med22 is shown in surface representation together with a ribbon model of Med11. The two views are related by a 180  rotation around a vertical
axis. (E) Superimposition of Ca traces of the four-helix bundle folds of Med11/22 (brown and cyan; this study) and Med7C/21 [orange and purple;
(31)]. (F) Ribbon-model representation of the complete Med7C/21 structure (pdb accession code 1YKE). The reported ﬂexible hinge region is
indicated.
Table 1. Data collection and reﬁnement statistics
Peak Inﬂection Remote
Data collection
Space group P 21212
Cell parameters (A ˚ )
a 148.5
b 173.8
c 101.6
Wavelength (A ˚ ) 0.9796 0.9797 0.9720
Resolution range (A ˚ )
a 100–2.05 (2.10–2.05) 100–2.2 (2.26–2.20) 100–2.3 (2.36–2.30)
Completeness (%) 98.9 (99.1) 98.9 (99.1) 98.9 (98.7)
Unique reﬂections 315134 (23359) 256151 (19022) 224540 (16639)
Redundancy 2.9 (3.0) 2.9 (2.9) 2.9 (2.8)
Rsym (%) 7.2 (57.8) 7.1 (52.6) 7.6 (55.9)
<I>/<sI> 10.8 (2.0) 11.5 (2.2) 11.5 (2.2)
Reﬁnement
Number of residues 1891
Number of non-hydrogen atoms 16483
Number of solvent molecules 964
RMS bond deviation (A ˚ ) 0.008
RMS angle deviation ( ) 0.968
Ramachandran plot (preferred/allowed) 99.3/0.7
Rcryst (%) 17.0
Rfree (%)
b 20.8
aThe numbers in parenthesis correspond to the highest resolution shell
b5% of the data were set aside for free Rfactor calculation.
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therefore a conserved architectural unit of the Mediator
head.
A highly conserved interaction patch on Med11/22
Despite the importance of the head module for PIC for-
mation, only few contacts between PIC components and
head module subunits have been reported. Thus, we
wanted to identify potential interaction surfaces on
Med11/22 that could account for contacts to PIC compo-
nents. Plotting sequence conservation (Figure 5A) and
electrostatic surface charge (Supplementary Figure S3)
onto the Med11/22 structure revealed a large, highly
conserved surface patch with exposed hydrophobic
residues on one side of the bundle domain. Several
known Med11/22 mutations (20,25,26), namely srb6-201
(med22-N59H), srb6-1 (med22-N86H), med11-T31A
(original annotation: med11-T47A), are located around
this patch (Figure 5A). Mutations reported to affect inter-
action of Med11 with Med22 or Med17 (20,36), namely
med11-V52D (original annotation: med11-V68D), med11-
G92S (original annotation: med11-G108S) and med11-
L66P (original annotation: med11-L82P), are however
located distant from this patch or in the hydrophobic
core (Figure 5A and Figure 1D). This suggests that the
Figure 3. A heterodimeric four-helix bundle building block in Mediator. Schematic depiction of Mediator subunits predicted to share the
heterodimeric bundle fold. a-helices from crystal structures or from predictions (61–63) are indicated as boxes drawn to scale. Helix a1, a2 and
C-terminal helical extensions are colored in black, gray and white, respectively. Check marks indicate experimentally conﬁrmed heterodimers
(co-expression and co-puriﬁcation). Structural homology to the published Med7C/21 structure was predicted with HHPred (http://toolkit.lmb.uni-
muenchen.de/hhpred) for all listed subunits except the highly divergent Sc subunits Med2 and Med3. The P-value and score for the HHPred searches
are given. When the human protein sequence was used for the HHPred search, the P-values are marked with an asterisk.
Figure 2. C-terminal extensions of Med11/22 are essential for viability.
Yeast complementation assays. MED11 and MED22 constructs
including 500bp upstream of the start codon and 300bp downstream
of the stop codon were cloned into a pRS315 plasmid (LEU2) and
transformed into the respective yeast shufﬂe strains. On 5FOA plates
the URA3 shufﬂe plasmid encoding the respective full-length gene is
shufﬂed out. Yeast cells lacking either the N- or C-terminus of Med11
or the C-terminus of Med22 are inviable. Cells lacking the N-terminal
helix of Med22 or the last 10 amino acids of Med11 display a slow
growth phenotype.
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components of the PIC.
To investigate the functional importance of this
patch we generated structure-based surface mutations.
Strains carrying double point mutations of adjacent
surface residues (med11-E17K/L24K, med22-L73E/K80E
and med22-K80E/L84E) exhibited various degrees of
temperature-sensitivity (Figure 5B). The med11-E17K/
L24K strain exhibited a strong growth defect at all tem-
peratures, similar to med111–105. However, unlike the
Med11 truncation, the patch mutation did not affect an-
choring of Med11/22 to Med17C in vitro (Figure 5C).
Since Med11/22 is essential for Med17 stability (18) we
puriﬁed Mediator from wild-type, med111–105 and
med11-E17K/L24K yeast strains to test complex integrity.
These mutations did apparently not affect Mediator archi-
tecture since Med7-TAP (middle module) co-immunopre-
cipitated subunits Med2 (tail module) and Med11 (head
module) (Figure 5D and Supplementary Figure S4). Thus,
the phenotype observed for the Med11 mutants does not
appear to be the result of impaired Mediator integrity, but
seems to be a direct effect of impaired Med11/22 inter-
actions with other factors.
Med11/22 is a functionally distinct submodule
To test whether mutations in Med11/22 affect transcrip-
tion in vivo, we performed genome-wide gene-expression
proﬁling of the med111–105 and med11-E17K/L24K yeast
strains (Figure 6A). The MED11 mutants form a distinct
cluster with a Pearson correlation coefﬁcient of 0.94,
correlating only moderately with med20D (head module),
med2D (tail module) and with mutations affecting the
previously described functional submodule Med7N/31
(middle module) (37) (Figure 6B and Supplementary
Table SII). In total, 604 and 450 genes were signiﬁcantly
changed (fold expression change >2-fold; P<0.05)
in med111–105 and med11-E17K/L24K, respectively
(Supplementary Figure S5A, Supplementary Table SII).
A total of 401 genes were signiﬁcantly changed in both
mutants, with 160 genes up-regulated and 241 genes down-
regulated. The number of signiﬁcantly changed genes in
both MED11 mutant strains is higher than in any other
Mediator mutant tested (Supplementary Figure S5B). The
effect on gene expression is rather pleiotropic without any
signiﬁcant enrichment for speciﬁc GO terms (38). This
indicates a distinct function of the Med11/22 subcomplex
in gene regulation and a more global role in contrast to
the more gene-speciﬁc roles of previously reported
non-essential Mediator submodules (29,37,39).
The Med11/22 surface patch functions in PIC
stabilization
Since Med11 was previously reported to stabilize the
TFIIK subcomplex of TFIIH and, to some extent, Pol
II at promoters (20), we performed chromatin immuno-
precipitations of Kin28, the kinase subunit of TFIIK and
the Pol II subunit Rpb3 in wild-type, med111–105 and
med11-E17K/L24K strains (Figure 6C). In the mutant
strains, we observed decreased occupancies for both
Kin28 and Rpb3 at active promoters, indicating a defect
in stable PIC formation. To test whether the decrease is a
direct effect of impaired Med11/22 function or an indirect
effect of global deregulation of gene expression, we per-
formed in vitro immobilized template assays with yeast
Figure 4. C-terminal extensions of Med11/22 bind a Med17 C-terminal
domain. (A) Co-expression in E. coli and co-puriﬁcation of Sc aC - t e r m i n a l
domain of Med17C (residues 377–687) with Sc 6His-Med22/Med11
constructs using nickel magnetic beads. A co-purifying contaminant is
marked with an asterisk. (B) Co-immunoprecipitation of the putative Sp
Med11-3HA with Sp Med7-TAP from Sp lysate using IgG agarose beads.
Med7 was eluted natively using tobacco etch virus protease. Med7 was
detected in the input using peroxidase/anti-peroxidase antibody complex.
Med11 was detected in both input and eluate using anti-HA antibody.
(C) Co-expression in E. coli and co-puriﬁcation of Sp Med17 (lanes 1–3)
and Sp Med17C (residues 257–545; lanes 4–6) with Sp His6-Med22/Med11
constructs using nickel magnetic beads.
Nucleic Acids Research, 2011,Vol.39, No. 14 6299nuclear extracts (Figure 6D). PICs were assembled on an
immobilized HIS4 yeast promoter in a Gcn4-dependent
manner, washed and subsequently analyzed by western
blot. Consistent with the in vivo results, both mutant
extracts displayed a decreased occupancy of Pol II after
washing. As expected, the occupancy of TFIIB, interact-
ing directly with Pol II, is also decreased. Mediator and
TFIID, which are recruited directly by the transcriptional
activator Gcn4 (40), remain unaffected. Consistently,
nuclear extracts from the MED11 mutant strains were
inactive in in vitro transcription assays (Figure 6E).
Since addition of puriﬁed wild-type Mediator to the
mutant extracts partially rescued the recruitment of the
basal machinery and consequently also transcriptional
activity, the observed defects can be directly linked to
Mediator function. These results show that the conserved
surface patch on the Med11/22 bundle is required for
stable PIC formation.
Figure 5. A conserved interaction patch on Med11/22. (A) Surface conservation of the Med11/22 four-helix bundle. Invariant and conserved
residues from yeast to human are highlighted in green and yellow, respectively. Residues of Med11 (brown) and Med22 (cyan) targeted by
mutagenesis in this study and in previous reports are indicated with arrows. The orientation is identical to Figure 1C. The two views are related
by a 180  rotation around the vertical axis. (B) Spot dilutions of yeast strains carrying structure-based mutations on the conserved surface patch and
viable truncations (Figure 2) on YPD plates at 30 C and 37 C. (C) Co-expression in E. coli and co-puriﬁcation of Sc Med17C with Sc 6His-Med22/
Med11 and Sc 6His-Med22/Med11-E17K/L24K using nickel magnetic beads. (D) Co-immunoprecipitation of Sc Med11-3HA (Mediator head
module) and Sc Med2 (Mediator tail module) with Sc Med7-TAP (Mediator middle module) from wild-type, med111–105 and med11-E17K/L24K
yeast strains.
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To understand the regulatory mechanisms of eukaryotic
transcription, a detailed structural and functional dissec-
tion of the involved multiprotein complexes is required. In
this study, we extend our previous structure–function
analysis of the general transcription co-activator
Mediator. We combine structural biology, yeast genetics,
biochemistry and gene-expression proﬁling, to deﬁne and
functionally characterize the Mediator subcomplex
Med11/22, to provide a more detailed understanding of
Mediator head module architecture and to obtain insights
into Mediator conservation and evolution. We report the
structure of a conserved four-helix bundle domain in
Med11/22 that puts reported mutations (20,36) into a mo-
lecular framework and identiﬁes a highly conserved
surface patch that is required for a distinct widespread
function of the Med11/22 subcomplex.
We suggest that the Med11/22 surface patch mediates
an essential interaction with TFIIH, because the previ-
ously described temperature-sensitive mutation med11-
T31A (20) locates near the patch. This mutation was
shown to decrease interaction of Med11 with the TFIIH
subunit Rad3 in yeast two-hybrid assays and promoter
occupancy of the TFIIH kinase module TFIIK. In
contrast to the mutation med11-T31A, which was dis-
covered genetically, the mutation med11-E17K/L24K
reported here was identiﬁed based on structural data
and had a strong general growth defect that allowed us
to conduct functional studies under standard growth con-
ditions. Chromatin immunoprecipitation showed a
Figure 6. Med11/22 is a functional Mediator submodule in vitro and in vivo.( A) Hierarchical cluster diagram (Pearson correlation) of genes
exhibiting signiﬁcantly altered mRNA levels (>2-fold, vertical axis) for different Mediator mutant strains (horizontal axis). Changes in mRNA
levels compared to the wild-type strain are depicted in yellow (up), blue (down) or black (no change). (B) Pearson correlation matrix for expression
proﬁles of different Mediator mutants (1, very high correlation; 0, no correlation;  1, very high anti-correlation). (C) Chromatin immunopre-
cipitation of Rpb3-TAP (Pol II) and Kin28-TAP (TFIIH kinase module) in wild-type, med111–105 and med11-E17K/L24K strains grown to early
exponential phase in YPD medium containing 2% glucose. Fold enrichment over a heterochromatic control region is shown for the yeast promoters
of a highly expressed gene (ILV5), a housekeeping gene (ADH1) and a glucose-repressed gene (GAL1). (D) In vitro PIC assembly of wild-type,
med111–105 and med11-E17K/L24K nuclear extracts (NE) on the immobilized HIS4 yeast promoter. PIC formation of mutant extracts was partially
rescued by adding 2pmol tandem-afﬁnity puriﬁed Mediator complex (TAP-Med) to the nuclear extracts prior to PIC assembly. Presence of Pol II
(Rpb3 & Rpb11), TFIIB, Mediator (Med17) and TFIID (Taf4) was tested by western Blot. (E) In vitro transcription assay with wild-type, med111–105
and med11-E17K/L24K nuclear extracts (NE) on the HIS4 yeast promoter. Order of addition is shown on top. Transcription was partially rescued by
adding 2pmol tandem-afﬁnity puriﬁed Mediator complex (TAP-Med).
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moters in vivo, indicating a defect in PIC formation. Yeast
nuclear extracts from the mutant strain were defective in
stable PIC formation and inactive in transcription in vitro.
The defects result from impairing the function of the Med11/
22 submodule and not the head module per se,s i n c e ,i nc o n -
trast to the reported med17 mutant srb4-138 (41), activator-
mediated recruitment of Mediator to the promoter was not
affected. Thus the Med11/22 submodule speciﬁcally func-
tions in promoting stable PIC formation. We propose that
the conserved submodular architecture of the Mediator
head enables multiple transient interactions with
PIC components, including TBP (16) and TFIIH (20)
(Figure 7), thereby stabilizing the PIC and facilitating
open complex formation and initial RNA synthesis.
Another intriguing observation is the presence of up to
six related helix bundle folds, to which about one-half of
the Mediator core subunits contribute. The presence of
related bundle domains in different Mediator modules
elucidates the evolutionary origin of Mediator. Large
protein complexes with high functional modularity
might generally have evolved through duplication of
genes-encoding dimers (42). For example, the 15-subunit
TFIID complex contains ﬁve heterodimeric subcomplexes
interacting through a common histone-fold domain
(43,44). Subsequent divergent evolution of paralogous
subunits could then generate asymmetry and diversiﬁca-
tion of protein interactions for functional specialization.
Rapid evolution of Mediator by dimer duplication and
diversiﬁcation beﬁts the ﬁnding that Mediator is only
present in eukaryotes although the general transcription
machineries are conserved between eukaryotes and
archaea.
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